Literature DB >> 10085143

Ligand binding properties of the very low density lipoprotein receptor. Absence of the third complement-type repeat encoded by exon 4 is associated with reduced binding of Mr 40,000 receptor-associated protein.

P M Rettenberger1, K Oka, L Ellgaard, H H Petersen, A Christensen, P M Martensen, D Monard, M Etzerodt, L Chan, P A Andreasen.   

Abstract

The very low density lipoprotein receptor (VLDLR) binds, among other ligands, the Mr 40,000 receptor-associated protein (RAP) and a variety of serine proteinase-serpin complexes, including complexes of the proteinase urokinase-type plasminogen activator (uPA) with the serpins plasminogen activator inhibitor-1 (PAI-1) and protease nexin-1 (PN-1). We have analyzed the binding of RAP, uPA.PAI-1, and uPA.PN-1 to two naturally occurring VLDLR variants, VLDLR-I, containing all eight complement-type repeats, and VLDLR-III, lacking the third complement-type repeat, encoded by exon 4. VLDLR-III displayed approximately 4-fold lower binding of RAP than VLDLR-I and approximately 10-fold lower binding of the most C-terminal one of the three domains of RAP. In contrast, the binding of uPA.PAI-1 and uPA.PN-1 to the two VLDLR variants was indistinguishable. Surprisingly, uPA.PN-1, but not uPA.PAI-1, competed RAP binding to both VLDLR variants. These observations show that the third complement-type repeat plays a crucial role in maintaining the contact sites needed for optimal recognition of RAP, but does not affect the proteinase-serpin complex contact sites, and that two ligands can show full cross-competition without sharing the same contacts with the receptor. These results elucidate the mechanisms of molecular recognition of ligands by receptors of the low density lipoprotein receptor family.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10085143     DOI: 10.1074/jbc.274.13.8973

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.

Authors:  Jan K Jensen; Anders Malmendal; Birgit Schiøtt; Sune Skeldal; Katrine E Pedersen; Leyla Celik; Niels Chr Nielsen; Peter A Andreasen; Troels Wind
Journal:  Biochem J       Date:  2006-11-01       Impact factor: 3.857

2.  Function and significance of very low density lipoprotein receptor subtype II.

Authors:  Jun Tian; Hao Bi; Yinghong Li; Pu Yang; Yiqiang Zong; Yu Wang; Shen Qu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

3.  Hepatitis C virus utilizes VLDLR as a novel entry pathway.

Authors:  Saneyuki Ujino; Hironori Nishitsuji; Takayuki Hishiki; Kazuo Sugiyama; Hiroshi Takaku; Kunitada Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-23       Impact factor: 11.205

4.  Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk.

Authors:  Jianbo Wu; Tammy L Strawn; Mao Luo; Liqun Wang; Rong Li; Meiping Ren; Jiyi Xia; Zhuo Zhang; Weizhong Ma; Tingting Luo; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-06       Impact factor: 8.311

5.  Preparation and characterization of polyclonal antibodies against VLDL receptor.

Authors:  Shen Qu; Tao Chen; Fan Wu; Yanhua Yin; Hao Bi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

6.  A neuronal VLDLR variant lacking the third complement-type repeat exhibits high capacity binding of apoE containing lipoproteins.

Authors:  Keiko Sakai; Oliver Tiebel; M Cecilia Ljungberg; Merry Sullivan; Hye-Jeong Lee; Tomoya Terashima; Rongying Li; Kunihisa Kobayashi; Hui-Chen Lu; Lawrence Chan; Kazuhiro Oka
Journal:  Brain Res       Date:  2009-04-22       Impact factor: 3.252

7.  The low-density lipoprotein receptor family: genetics, function, and evolution.

Authors:  W J Schneider; J Nimpf; C Brandes; M Drexler
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.